CASIF (CASI Pharmaceuticals) Price-to-Tangible-Book: (As of Sep. 13, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CASIF CASI Pharmaceuticals Inc CASIF
26 GF Score
Price $0.14
GF Value $1.04
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is CASI Pharmaceuticals Price-to-Tangible-Book?

As of today (2026-09-13), CASI Pharmaceuticals's share price is $0.13999. CASI Pharmaceuticals's Tangible Book per Share of Jun. 2026 for the quarter that ended in Jun. 2026 was $-2.85. Hence, CASI Pharmaceuticals's Price to Tangible Book Ratio of today is .

The historical rank and industry rank for CASI Pharmaceuticals's Price-to-Tangible-Book or its related term are showing as below:

During the past 13 years, CASI Pharmaceuticals's highest Price to Tangible Book Ratio was 27.21. The lowest was 0.55. And the median was 4.29.

CASIF's Price-to-Tangible-Book is not ranked *
in the Biotechnology industry.
Industry Median: 3.25
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, CASI Pharmaceuticals's share price is $0.13999. CASI Pharmaceuticals's Book Value per Sharefor the quarter that ended in Jun. 2026 was $-2.84. Hence, CASI Pharmaceuticals's P/B Ratio of today is .

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

CASI Pharmaceuticals Price-to-Tangible-Book Related Terms

CASI Pharmaceuticals Price-to-Tangible-Book Historical Data

* Premium members only.

The historical data trend for CASI Pharmaceuticals's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CASI Pharmaceuticals Price-to-Tangible-Book Chart

CASI Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Price-to-Tangible-Book
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.55 0.55 4.29 27.21 0.00

CASI Pharmaceuticals Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.36 27.21 0.00 0.00 0.00

CASIF vs CMND, VBIO, BIXT: Price-to-Tangible-Book Comparison

For the Biotechnology subindustry, CASI Pharmaceuticals's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CASI Pharmaceuticals Price-to-Tangible-Book vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CASI Pharmaceuticals's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where CASI Pharmaceuticals's Price-to-Tangible-Book falls into.


CASIF
26GF Score
CASI Pharmaceuticals Inc CASIF
Price-to-Tangible-Book is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CASI Pharmaceuticals Price-to-Tangible-Book Calculation

CASI Pharmaceuticals's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Jun. 2026 )
=0.13999/-2.845
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price to Tangible Book=Market Cap/Tangible Equity
=Market Cap/(Total Stockholders Equity-Preferred Stock-Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Is CASI Pharmaceuticals (CASIF) Overvalued in 2026?

Based on GuruFocus' analysis, CASI Pharmaceuticals stock appears to be undervalued. The current stock price of $0.14 is trading 86.5% below its estimated GF Value™ of $1.04. GuruFocus considers CASI Pharmaceuticals to be Possible Value Trap.

Key valuation signals for CASIF:

  • Price-to-Tangible-Book:
  • GF Value™: $1.04 vs. price of $0.14 (86.5% below fair value)
  • GF Score™: 26/100 with 7 warning signs

No single metric tells the full story. See the CASIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CASI Pharmaceuticals Business Description

Address Jianguo Road, No. 81, Room 1701-1702, China Central Office Tower 1, Huamao Office Building, Chaoyang District, Beijing, CHN, 100025
CASI Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases. Additionally, the company manages its other assets, including EVOMELA, FOLOTYN, CNCT19, BI-1206, and CB-5339, with a primary strategic emphasis on advancing CID-103 toward key clinical and regulatory milestones. It also distributes YuTuo (Zimberelimab), a fully human anti-PD-1 monoclonal antibody for patients with relapsed or refractory classical Hodgkin's lymphoma and recurrent or metastatic cervical cancer. Geographically, the company's revenue is solely generated in Mainland China.
26GF Score

Get the complete analysis for CASIF

Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.14
Price
$1.04
GF Value